Making Headway in the Quest for COVID-19 Cell Therapies – Technology Networks

Type of cell therapy Rationale Proposed benefits Convalescent plasma therapy Plasma from donors who have recovered from COVID-19 may contain antibodies to SARS-CoV-2. Suppress the virus and modify the inflammatory response. Immunotherapy, including the transfer of T cells from convalescent donors and engineered NK cells  Goal is to develop cells that will help the host modify various inflammatory/immune responses. Reduce overall disease severity. Mesenchymal stem cells/medicinal signaling cells and their derivatives Potential immunomodulatory effect via secretion of cytokines, chemokines, growth factors and extracellular vesicles, or direct interaction with immune cells. Limit inflammation and limit lung fibrosis. Lung stem cells (through clonal expansion or iPSC differentiation) Alveolar regeneration. Improve endogenous repair of damaged tissue in lungs of recovered patients suffering from alveolar damage. Exosomes, derived from various sources e.g. T cells, amniotic fluid Five COVID-19 exosome clinical trials have been registered. Mechanisms unknown, despite the promising therapeutic potential of exosomes.